Hi Floyds Just topped up last week at 5.8c, I think a little...

Hi Floyds
Just topped up last week at 5.8c,
I think a little more patients and SIE will deliver ,

I like sticking with real companies with a real business model and good management .




___________________________________________
SciGen Limited ARBN 101 318 852 Level 7, 2 Bligh Street, Sydney NSW 2000 Australia
Telephone : + 61 2 9234 1700 Facsimile : + 61 2 9234 1777 Website: www.scigen.com.au
ASX Announcement and Media Release
13 December, 2004
SciGen Limited and Intercell AG

SciGen Limited and Intercell AG sign an exclusive agreement for the development of a therapeutic Hepatitis B vaccine
International biopharmaceutical company SciGen Limited and Vienna-based biotechnology
company Intercell AG announced today the signing of an exclusive agreement for the
development of a new therapeutic Hepatitis B virus [“HBV”] vaccine.
A therapeutic HBV vaccine, providing a cure for HBV would significantly reduce the burden of
the disease and meet a high medical demand in an attractive market.

Currently there is no therapeutic vaccine against Hepatitis B available.

The proposed therapeutic vaccine combines SciGen’s already licensed PreS1-, PreS2-

Hepatitis B virus antigen (Sci-B-Vac™) with Intercell’s novel synthetic Immunizer IC 31™ as an
adjuvant that induces the type of immune response needed to overcome the infection.
Intercell will formulate the vaccine for the clinical development and both parties will share the
development of the product.
Professor Daniel Shouval, internationally recognized liver disease specialist, Dean of the
Hadassah University Hospital Medical School in Jerusalem and member of SciGen’s Scientific
Advisory Board:
“This development provides a very significant pportunity for tackling a widespread and alarming disease.

The consequences of chronic hepatitis B infection include
liver cirrhosis and liver cancer, both incurable diseases usually with tragic outcomes.”
“Any therapeutic agent developed to comprehensively and successfully treat hepatitis Binfection would be regarded by the international medical community as a revolutionary

promising development in the quest for such a therapeutic agent”, Professor Shouval added.
Gerd Zettlmeissl, Chief Operating Officer of Intercell AG, stated: “This collaboration is another
important milestone for both companies.

It fully combines the strength of Intercell’s latest “state
of the art” adjuvant technologies and allows us to further leverage past investments in our
technologies and our expertise in therapeutic viral vaccines”.
Mark Compton, SciGen’s Managing Director: “Whilst this is clearly still at an early stage, the prospect of developing such a blockbuster product is very exciting for both companies.
The incidence of hepatitis B in the Asia Pacific Region is reaching alarming levels. Affordable and available treatment for this infection is very much on the agenda for governments and international agencies such as the WHO.
The combination of our Sci-B.Vac™ and Intercell’s
IC31™ allows us to develop an important product for this severe disease.”
The Development Agreement between SciGen and Intercell provides a sharing of development costs, a result is a joint ownership of a future product.
Further financial details are not disclosed.
Facts on Hepatitis B
Hepatitis B is a serious global public health problem. The virus is transmitted by contact with
blood or body fluids of an infected person and leads to inflammation of the liver, liver cirrhosis
and cancer.
According to estimations of the WHO (World Health Organisation):
» 1 out of 3 people have been infected with the hepatitis B virus
» 400 million people are chronic carriers of HBV
» Hepatitis B is the leading cause of liver cancer
» The World Health Organization estimates that hepatitis B infections lead to more than one
million deaths every year
__________________
_________________________________________________________________________________________________________________
SciGen Limited ARBN 101 318 852 Level 7, 2 Bligh Street, Sydney NSW 2000 Australia
Telephone : + 61 2 9234 1700 Facsimile : + 61 2 9234 1777 Website: www.scigen.com.au
Infected and chronic hepatitis B patients are currently treated with interferon or lamivudine, a
very expensive therapy which is not affordable to most patients in developing countries.
There is no therapeutic vaccine against hepatitis B on the market.
About Intercell
Intercell is a fast growing biotechnology company with a clear strategy and focus on the design
and development of novel vaccines for prophylactic and therapeutic treatment of diseases with
substantial unmet needs. The Company’s unique proposition is based on the combination of
antigens and immunizers (adjuvants) derived from its proprietary technology platforms, as well
as in-house GMP facilities. Intercell’s technology has been endorsed by collaborative
agreements with global pharmaceutical companies including Aventis Pasteur, Merck&Co, Inc.
and Statens Serum Institut. Intercell has a broad development pipeline with a vaccine for
Japanese Encephalitis about to enter Phase 3, a vaccine for Hepatitis C undergoing Phase 2
trials, and five products focused on infectious diseases in the pre-clinical phase. To date, the
Company has raised €100m in external funding from international blue chip investors.
For more information please visit: www.intercell.com